Designing drug candidates exhibiting polypharmacology is one of the strategies adopted by medicinal chemists to address multifactorial diseases. Metabolic disease is one such multifactorial disorder characterized by hyperglycaemia, hypertension and dyslipidaemia among others. In this paper we report a new class of molecular framework combining the pharmacophoric features of DPP4 inhibitors with those of ACE inhibitors to afford potent dual inhibitors of DPP4 and ACE.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmcl.2017.04.036 | DOI Listing |
Publication Analysis
Top Keywords
approaches development
4
development chimeric
4
chimeric dpp4/ace
4
inhibitors
4
dpp4/ace inhibitors
4
inhibitors treating
4
treating metabolic
4
metabolic syndrome
4
syndrome designing
4
designing drug
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!